Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 23216455)

1.

Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment.

Reményi G, Szász R, Debreceni IB, Szarvas M, Batár P, Nagy B Jr, Kappelmayer J, Udvardy M.

Platelets. 2013;24(6):486-92. doi: 10.3109/09537104.2012.731112. Epub 2012 Dec 5.

PMID:
23216455
2.

Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia.

Tsantes AE, Nikolopoulos GK, Tsirigotis P, Zoi K, Zomas A, Kapsimali V, Kopterides P, Chondropoulos S, Dervenoulas J, Mantzios G.

Blood Coagul Fibrinolysis. 2011 Sep;22(6):457-62. doi: 10.1097/MBC.0b013e3283488494.

PMID:
21836466
3.
4.

Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.

Panova-Noeva M, Marchetti M, Spronk HM, Russo L, Diani E, Finazzi G, Salmoiraghi S, Rambaldi A, Barbui T, Ten Cate H, Falanga A.

Am J Hematol. 2011 Apr;86(4):337-42. doi: 10.1002/ajh.21974. Erratum in: Am J Hematol. 2011 May;86(5):466. Finazzi, Good [corrected to Finazzi, Guido];Rambaldi, Aueesandrd [corrected to Rambaldi, Alessandro];Barbui, Titiano [corrected to Barbui, Tiziano]; Ten Cate, Huao [corrected to Ten Cate, Hugo].

PMID:
21442635
5.

Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.

Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F.

Am J Hematol. 2009 Feb;84(2):102-8. doi: 10.1002/ajh.21338.

PMID:
19105233
6.

The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.

Treliński J, Tybura M, Smolewski P, Robak T, Chojnowski K.

Blood Coagul Fibrinolysis. 2009 Dec;20(8):646-51. doi: 10.1097/MBC.0b013e32832f6c5b.

PMID:
19741509
7.

Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.

Cella G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L, Barbui T, Falanga A.

Thromb Haemost. 2010 Jul;104(1):151-6. doi: 10.1160/TH09-09-0663. Epub 2010 Apr 29.

PMID:
20431848
8.

Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.

Treliński J, Wierzbowska A, Krawczyńska A, Sakowicz A, Pietrucha T, Smolewski P, Robak T, Chojnowski K.

Leuk Lymphoma. 2010 Sep;51(9):1727-33. doi: 10.3109/10428194.2010.500435.

PMID:
20615083
9.

Dysfunction of the PI3 kinase/Rap1/integrin α(IIb)β(3) pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia.

Moore SF, Hunter RW, Harper MT, Savage JS, Siddiq S, Westbury SK, Poole AW, Mumford AD, Hers I.

Blood. 2013 Feb 14;121(7):1209-19. doi: 10.1182/blood-2012-05-431288. Epub 2012 Dec 13.

10.

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten Cate H, Falanga A.

Blood. 2011 Sep 1;118(9):2599-601. doi: 10.1182/blood-2011-02-339655. Epub 2011 Jul 12.

11.

Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.

Randi ML, Brunati AM, Scapin M, Frasson M, Deana R, Magrin E, Fabris F, Donella-Deana A.

Blood. 2010 Jan 21;115(3):667-76. doi: 10.1182/blood-2008-12-196535. Epub 2009 Nov 12.

12.

Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.

Hattori N, Fukuchi K, Nakashima H, Maeda T, Adachi D, Saito B, Yanagisawa K, Matsuda I, Nakamaki T, Gomi K, Tomoyasu S.

Int J Hematol. 2008 Sep;88(2):181-8. doi: 10.1007/s12185-008-0129-9. Epub 2008 Jul 10.

PMID:
18612778
13.

Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A.

Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.

15.

Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.

Dua V, Yadav SP, Kumar V, Saxena R, Sachdeva A.

Int J Hematol. 2012 Dec;96(6):810-3. doi: 10.1007/s12185-012-1193-8. Epub 2012 Oct 7.

PMID:
23054653
16.

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.

Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T.

Exp Hematol. 2007 May;35(5):702-11. Erratum in: Exp Hematol. 2007 Sep;35(9):1476.

PMID:
17577920
17.

Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.

Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F.

Haematologica. 2006 Feb;91(2):169-75.

18.

Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation.

Presseizen K, Friedman Z, Shapiro H, Radnay J, Ellis MH.

Clin Appl Thromb Hemost. 2002 Jan;8(1):33-9.

PMID:
11991237
19.

[Correlation of thrombosis with increased platelet turnover in essential thrombocythemia].

Gao XP, Liu ZM, Li J, Han XY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Feb;14(1):165-7. Chinese.

PMID:
16584616
20.

Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.

Petrides PE, Siegel F.

Blood Cells Mol Dis. 2006 May-Jun;36(3):379-84. Epub 2006 Mar 24. Review.

PMID:
16563815
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk